.png){kind=icon}
.png){kind=icon}
Return
Three years of ocular proton therapy in the Netherlands, clinical results
.png){kind=icon}
OA
AI
C
M
L
E
N
S
P
C
J
J
A
A
J
N
K
DOI：10.1111/aos.70195.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Uveal melanoma (UM) is a rare cancer with rising number of diagnosis (143 diagnoses in 1990 to 226 in 2023) in the Netherlands. Most patients are treated locally with Ruthenium-106 brachytherapy (±102/year). Patients were referred for proton therapy (PT) to Switzerland in the past, but PT is available in the Netherlands from January 2020 onwards. The purpose of this study is to assess the oncological and ophthalmological outcomes of the current cohort and compare with the published historic cohort.
Keywords:
clinical results
ocular cancer
ocular melanoma
proton therapy
radiotherapy
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
2.8
Papers:
1.1W
Citations:
1.1W
Organization
Cited Papers